Assessment Status | Rapid Review Complete |
HTA ID | 23005 |
Drug | Burosumab |
Brand | Crysvita® |
Indication | Burosumab (Crysvita®) is indicated for X-linked hypophosphataemia in adult patients. |
Assessment Process | |
Rapid review commissioned | 03/02/2023 |
Rapid review completed | 14/03/2023 |
Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of burosumab compared with the current standard of care. |